Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
400 Cell-Penetrating Peptides: Processes and Applications<br />
AntpHD mutant behavior, 25<br />
penetratin-1 peptide, 25–26<br />
HPLC, quantification by, 269–270<br />
3 H radiolabeling, quantification by, 266–267<br />
h-region peptides, 117–122, see also Membrane<br />
translocating (MTS) peptides<br />
HSP70 proteins, 305<br />
Hydrophobicity<br />
atomic surface, 191–193<br />
molecular hydrophobicity potential (MHP),<br />
199–202, 206–208<br />
Hydrophobic membrane translocating sequence<br />
peptides, 115–140, see also<br />
Membrane translocating sequence<br />
(MTS) peptides<br />
Hydrophobic peptides, structure prediction<br />
modeling, 202–204<br />
I<br />
125 I radiolabeling, quantification by, 266–267<br />
Immunodetection, quantification by, 270<br />
Incubation, of cells with CPPs, 279–280<br />
Inhibition zone assay, 385<br />
Integrin β 3 h-region, 122<br />
Interfacial electrostatics, 229–231<br />
Internalization, 287–293, see also Uptake; Uptake<br />
kinetics<br />
comparisons of CPPs and, 290–291<br />
penetratins, 26–30<br />
blood–brain barrier and, 39–40<br />
direct perfusion in CNS, 39<br />
immune system, 39<br />
in vivo with penatratin-derived vectors,<br />
39–40<br />
peptide–lipid interactions, 28–29<br />
peptides in blood vessels, 39<br />
proposed models, 29–30<br />
structural parameters and translocation,<br />
26–28<br />
vesicular, 177<br />
via receptor, 177–179<br />
Interphase region, 229–231<br />
Interpretative criteria, 239–240<br />
Ion pump uptake assays, 252<br />
K<br />
KALA peptide, 356–357<br />
Kaposi fibroblast growth factor (kFGF, FGF-4),<br />
117–118, 120–122, 131<br />
Kar2p (BiP) protein, 305<br />
KF<strong>FK</strong>F<strong>FK</strong>F<strong>FK</strong> peptide, 357<br />
Kinetics, uptake, 277–293, see also Uptake<br />
kinetics<br />
L<br />
Lactate dehydrogenase leakage assay, 249<br />
Large unicellular vesicles (LUVs), 227<br />
Leakage, as mechanism of antimicrobial action,<br />
383–384<br />
Leakage assays, 283<br />
Lhs1p protein, 305<br />
Lipid perturbation, 193–194<br />
Lipid vesicles, determination of reduction rate<br />
constants, 271–272<br />
Liposomes, 226–228<br />
Loligomers, in nucleic acid delivery, 357–358<br />
Lymphocytes, transduction into, 370<br />
M<br />
Magainin, 236–238, 240<br />
Magnetic cell labeling with Tat protein, 336–343<br />
CLIO-Tat internalization into lymphocyte and<br />
CD34+ subsets, 336–337<br />
internalization of paramagnetic chelates,<br />
342–343<br />
internalization of superparamagnetic<br />
nanoparticles, 336<br />
label distribution in dividing cell populations,<br />
337–338<br />
results in vitro, 338–339<br />
results in vivo, 339–340<br />
toxicity/nontoxicity, 338<br />
in vivo MR imaging of Tat-labeled cells,<br />
340–342<br />
Maltoporin, 204–206<br />
MAP and MAP analogues, uptake kinetics, 290<br />
MAPs, 71–92<br />
experimental methods, 87–90<br />
cell culture, 87<br />
confocal laser scanning microscopy, 88–90<br />
HPLC analysis, 88<br />
uptake experiments, 87–88<br />
introducing history, 72–73<br />
toxicity, 252–253<br />
uptake<br />
mammalian cell experiments, 84–87<br />
mechanistic aspects, 73–76<br />
structural requirements, 76–84<br />
Mastoparan, 58, 59, see also Transportan<br />
Mastoparan X, 236–238, 240<br />
Mechanisms and interactions, see also specific<br />
topics<br />
backbone and side chain variations, 141–160<br />
biophysical studies, 223–244<br />
membrane interactions, 163–183<br />
quantification of CPPs and cargoes, 263–275<br />
signal peptides, 295–324